Aurinia Pharmaceuticals (AUPH) Q4 2024 earnings summary

Executive summary

• Achieved significant revenue growth in Q4 and full year 2024, with record net product sales for Lupkynis, driven by increased market penetration in lupus nephritis (LN).

• Returned to profitability with Q4 net income of $1.4M and full-year net income of $5.8M, compared to significant losses in 2023.

• Strategic restructuring in 2024 led to improved cash flow and operational efficiency, supporting future growth and flexibility.

• Focused commercial strategy targets academic centers, rheumatology prescribers, and hospital segments to drive further adoption.

• Advanced pipeline with initiation of Phase 1 study for AUR-200, a dual APRIL inhibitor, with results expected in Q2 2025.

Financial highlights

• Q4 2024 total revenue: $59.9M, up 33% year-over-year; full year 2024 total revenue: $235.1M, up 34%.

• Q4 2024 Lupkynis net product sales: $57.6M, up 36% year-over-year; full year 2024: $216.2M, up 36%.

• Q4 2024 net income: $1.4M ($0.01 EPS) vs. net loss of $26.9M in Q4 2023; full year 2024 net income: $5.8M ($0.04 EPS) vs. net loss of $78M in 2023.

• Cash, cash equivalents, restricted cash, and investments: $358.5M as of Dec 31, 2024.

• Cash flow from operations: $44.4M in 2024 vs. cash used of $33.5M in 2023.

Outlook and guidance

• 2025 total revenue expected in the range of $250–$260M; net product sales guidance for Lupkynis: $240–$250M.

• Continued focus on commercial execution and operational efficiency to sustain growth.

• Initial phase I results for AUR-200 anticipated in Q2 2025.